Surgery improves outcomes in metastatic neuroendocrine tumors

Evidence suggests that surgical intervention, prior to peptide receptor radionuclide therapy, significantly enhances progression-free survival for patients with metastatic gastroenteropancreatic neuroendocrine tumors. In a study of 89 well-matched patients, those who underwent surgery had a median progression-free survival of 26.1 months, compared to 15.6 months in the no-surgery group (p = .04). Furthermore, liver debulking demonstrated the greatest impact, with patients achieving a median survival of 26.2 months.